Parecoxib
Dynastat (parecoxib) is a small molecule pharmaceutical. Parecoxib was first approved as Dynastat on 2002-03-22. It has been approved in Europe to treat postoperative pain.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
44 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative pain | D010149 | G89.18 | — | 1 | 2 | 11 | 4 | 18 | |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 2 | 2 | — | 4 |
| Anesthesia | D000758 | — | — | 1 | 1 | — | 2 | ||
| Inflammation | D007249 | — | — | — | 1 | — | 1 | ||
| Gastrointestinal neoplasms | D005770 | C26.9 | — | — | — | 1 | — | 1 | |
| Rupture | D012421 | — | — | — | 1 | — | 1 | ||
| Renal colic | D056844 | EFO_1001412 | N23 | — | — | — | 1 | — | 1 |
| Emergence delirium | D000071257 | — | — | — | 1 | — | 1 | ||
| Hyperalgesia | D006930 | — | — | — | 1 | — | 1 | ||
| Perioperative care | D019990 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | 1 | — | 1 | 2 |
| Rib fractures | D012253 | — | — | 1 | — | — | 1 | ||
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | 1 | — | — | 1 |
| Colic | D003085 | HP_0011848 | R10.83 | — | — | 1 | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anaplasia | D000708 | — | — | — | — | 1 | 1 | ||
| Causalgia | D002422 | EFO_1000854 | — | — | — | — | 1 | 1 | |
| Laparoscopy | D010535 | — | — | — | — | 1 | 1 | ||
| Platelet aggregation | D010974 | GO_0070527 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PARECOXIB |
| INN | parecoxib |
| Description | Parecoxib is an N-acylsulfonamide resulting from the formal condensation of valdecoxib with propionic acid. It is a prodrug for valdecoxib. It has a role as a cyclooxygenase 2 inhibitor, a non-narcotic analgesic, a non-steroidal anti-inflammatory drug and a prodrug. It is a member of isoxazoles and a N-sulfonylcarboxamide. It is functionally related to a valdecoxib. |
| Classification | Small molecule |
| Drug class | cyclooxygenase-2 inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 198470-84-7 |
| RxCUI | 279950 |
| ChEMBL ID | CHEMBL1206690 |
| ChEBI ID | 73038 |
| PubChem CID | 119828 |
| DrugBank | DB08439 |
| UNII ID | 9TUW81Y3CE (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,025 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,009 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more